{"id":1139,"date":"2021-12-15T20:02:00","date_gmt":"2021-12-16T01:02:00","guid":{"rendered":"https:\/\/paragoninstitute.org\/index.php\/2021\/12\/15\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help-2\/"},"modified":"2024-04-19T16:00:35","modified_gmt":"2024-04-19T20:00:35","slug":"covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help","status":"publish","type":"post","link":"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/","title":{"rendered":"Covid-19 Treatments and the FDA: A Sense of Urgency Might Help"},"content":{"rendered":"\r\n

AS\u00a0the Delta variant surges in various locales and the new\u00a0Omicron variant\u00a0expands around the globe, public officials are beginning to reimpose Covid-19 restrictions. The Food and Drug Administration, though, seems to lack the same sense of urgency.<\/p>\r\n\r\n\r\n\r\n

The agency is considering two new antiviral pills that have been found to cut Covid-19 hospitalizations and deaths in people treated soon after they become symptomatic.<\/p>\r\n\r\n\r\n\r\n

If authorized, the pills would enable early Covid-19 to be treated at home with a five-day course of treatment \u2014 a marked improvement upon the treatments that are presently on offer.<\/p>\r\n\r\n\r\n\r\n

The\u00a0only currently FDA-authorized antiviral\u00a0for Covid-19, Remdesivir, must be administered intravenously in a hospital setting, making it burdensome and expensive to use. Monoclonal antibodies \u2014 laboratory-produced molecules that block the virus that causes Covid-19 from attaching to human cells \u2014\u00a0have been granted FDA emergency-use authorizations (EUA), but are costly, difficult to manufacture, and also require intravenous administration.<\/p>\r\n\r\n\r\n\r\n

The most promising of the new oral antivirals is Pfizer\u2019s Paxlovid. The company halted a trial of the drug when an interim analysis demonstrated an 89 percent reduction in risk of hospitalization or death compared with placebo in nonhospitalized high-risk adults with Covid-19. Pfizer\u00a0applied for an EUA\u00a0a month ago on November 16, 2021.<\/p>\r\n\r\n\r\n\r\n

The company has\u00a0announced\u00a0that a final analysis has confirmed the drug\u2019s high effectiveness with the added bonus that it appears to be effective against Omicron. A second clinical trial in low-risk, unvaccinated people, as well as in vaccinated people at high risk for Covid-19 complications, found that Paxlovid cut hospitalizations by 70 percent compared with placebo. Yet the FDA has still not scheduled a meeting of its advisory committee to review the Paxlovid EUA.<\/p>\r\n\r\n\r\n\r\n

Read the full article<\/a> in National Review.<\/p>\r\n","protected":false},"excerpt":{"rendered":"

AS\u00a0the Delta variant surges in various locales and the new\u00a0Omicron variant\u00a0expands around the globe, public officials are beginning to reimpose Covid-19 restrictions. The Food and Drug Administration, though, seems to…<\/p>\n","protected":false},"author":3,"featured_media":5159,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[754],"tags":[706,387],"external-media-outlet":[798],"featured":[],"location":[],"publication-type":[717],"acf":[],"yoast_head":"\nCovid-19 Treatments and the FDA: A Sense of Urgency Might Help<\/title>\n<meta name=\"description\" content=\"The FDA is considering two antiviral pills that have proved highly effective. Why is it still dragging its feet?\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Covid-19 Treatments and the FDA: A Sense of Urgency Might Help\" \/>\n<meta property=\"og:description\" content=\"The FDA is considering two antiviral pills that have proved highly effective. Why is it still dragging its feet?\" \/>\n<meta property=\"og:url\" content=\"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/\" \/>\n<meta property=\"og:site_name\" content=\"Paragon Health Institute\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-16T01:02:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-19T20:00:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Dr. Joel Zinberg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Covid-19 Treatments and the FDA: A Sense of Urgency Might Help\" \/>\n<meta name=\"twitter:description\" content=\"The FDA is considering two antiviral pills that have proved highly effective. Why is it still dragging its feet?\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Joel Zinberg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/\",\"url\":\"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/\",\"name\":\"Covid-19 Treatments and the FDA: A Sense of Urgency Might Help\",\"isPartOf\":{\"@id\":\"https:\/\/paragoninstitute.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp\",\"datePublished\":\"2021-12-16T01:02:00+00:00\",\"dateModified\":\"2024-04-19T20:00:35+00:00\",\"author\":{\"@id\":\"https:\/\/paragoninstitute.org\/#\/schema\/person\/41b77f32c6e25fc8e53850a28b09f2ff\"},\"description\":\"The FDA is considering two antiviral pills that have proved highly effective. Why is it still dragging its feet?\",\"breadcrumb\":{\"@id\":\"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/#primaryimage\",\"url\":\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp\",\"contentUrl\":\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp\",\"width\":1920,\"height\":1080,\"caption\":\"IStock 1213293784 10\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/paragoninstitute.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Covid-19 Treatments and the FDA: A Sense of Urgency Might Help\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/paragoninstitute.org\/#website\",\"url\":\"https:\/\/paragoninstitute.org\/\",\"name\":\"Paragon Health Institute\",\"description\":\"Health Policy Solutions Americans Can Trust\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/paragoninstitute.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/paragoninstitute.org\/#\/schema\/person\/41b77f32c6e25fc8e53850a28b09f2ff\",\"name\":\"Dr. Joel Zinberg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/paragoninstitute.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2023\/11\/joel-zinberg.webp\",\"contentUrl\":\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2023\/11\/joel-zinberg.webp\",\"caption\":\"Dr. Joel Zinberg\"},\"description\":\"Joel M. Zinberg, M.D., J.D. is the Director of the Public Health and American Well-Being Initiative at Paragon Health Institute, and a\u00a0senior fellow with the Competitive Enterprise Institute. A native New Yorker, he recently completed two years as\u00a0General Counsel and Senior Economist at the Council of Economic Advisers\u00a0in the Executive Office of the President. Dr. Zinberg has practiced general and oncologic surgery in New York for nearly 30 years at the Mount Sinai Hospital and Icahn School of Medicine, where he remains an\u00a0Associate Clinical Professor of Surgery. He has been involved with health policy issues and the interaction between law and medicine for his entire career. For 10 years, Dr. Zinberg taught as a lecturer at the Columbia University Law School, where he created a course on the legal, policy and ethical issues surrounding organ transplantation. He served for many years on the New York State Board of Professional Medical Conduct and on Mount Sinai\u2019s Ethics Committee and Institutional Review Board. He is a past President and Trustee of the New York County Medical Society, and between 2015 and 2017, served as a visiting scholar at the American Enterprise Institute. Dr. Zinberg has written for publications as varied as the Journal of the American Medical Association, the Bulletin of the American College of Surgeons, The Wall Street Journal, City Journal, and law reviews, and authored book chapters on legal and policy issues associated with organ transplantation. Dr. Zinberg earned his B.A. in economics with High Honors, Phi Beta Kappa, from Swarthmore College, his J.D. degree from the Yale Law School, and his M.D. from the Columbia University College of Physicians and Surgeons.\",\"url\":\"https:\/\/paragoninstitute.org\/author\/joel-zinberg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Covid-19 Treatments and the FDA: A Sense of Urgency Might Help","description":"The FDA is considering two antiviral pills that have proved highly effective. Why is it still dragging its feet?","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/","og_locale":"en_US","og_type":"article","og_title":"Covid-19 Treatments and the FDA: A Sense of Urgency Might Help","og_description":"The FDA is considering two antiviral pills that have proved highly effective. Why is it still dragging its feet?","og_url":"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/","og_site_name":"Paragon Health Institute","article_published_time":"2021-12-16T01:02:00+00:00","article_modified_time":"2024-04-19T20:00:35+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp","type":"image\/webp"}],"author":"Dr. Joel Zinberg","twitter_card":"summary_large_image","twitter_title":"Covid-19 Treatments and the FDA: A Sense of Urgency Might Help","twitter_description":"The FDA is considering two antiviral pills that have proved highly effective. Why is it still dragging its feet?","twitter_image":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp","twitter_misc":{"Written by":"Dr. Joel Zinberg","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/","url":"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/","name":"Covid-19 Treatments and the FDA: A Sense of Urgency Might Help","isPartOf":{"@id":"https:\/\/paragoninstitute.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/#primaryimage"},"image":{"@id":"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/#primaryimage"},"thumbnailUrl":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp","datePublished":"2021-12-16T01:02:00+00:00","dateModified":"2024-04-19T20:00:35+00:00","author":{"@id":"https:\/\/paragoninstitute.org\/#\/schema\/person\/41b77f32c6e25fc8e53850a28b09f2ff"},"description":"The FDA is considering two antiviral pills that have proved highly effective. Why is it still dragging its feet?","breadcrumb":{"@id":"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/#primaryimage","url":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp","contentUrl":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp","width":1920,"height":1080,"caption":"IStock 1213293784 10"},{"@type":"BreadcrumbList","@id":"https:\/\/paragoninstitute.org\/public-health\/covid-19-treatments-and-the-fda-a-sense-of-urgency-might-help\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/paragoninstitute.org\/"},{"@type":"ListItem","position":2,"name":"Covid-19 Treatments and the FDA: A Sense of Urgency Might Help"}]},{"@type":"WebSite","@id":"https:\/\/paragoninstitute.org\/#website","url":"https:\/\/paragoninstitute.org\/","name":"Paragon Health Institute","description":"Health Policy Solutions Americans Can Trust","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/paragoninstitute.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/paragoninstitute.org\/#\/schema\/person\/41b77f32c6e25fc8e53850a28b09f2ff","name":"Dr. Joel Zinberg","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/paragoninstitute.org\/#\/schema\/person\/image\/","url":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2023\/11\/joel-zinberg.webp","contentUrl":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2023\/11\/joel-zinberg.webp","caption":"Dr. Joel Zinberg"},"description":"Joel M. Zinberg, M.D., J.D. is the Director of the Public Health and American Well-Being Initiative at Paragon Health Institute, and a\u00a0senior fellow with the Competitive Enterprise Institute. A native New Yorker, he recently completed two years as\u00a0General Counsel and Senior Economist at the Council of Economic Advisers\u00a0in the Executive Office of the President. Dr. Zinberg has practiced general and oncologic surgery in New York for nearly 30 years at the Mount Sinai Hospital and Icahn School of Medicine, where he remains an\u00a0Associate Clinical Professor of Surgery. He has been involved with health policy issues and the interaction between law and medicine for his entire career. For 10 years, Dr. Zinberg taught as a lecturer at the Columbia University Law School, where he created a course on the legal, policy and ethical issues surrounding organ transplantation. He served for many years on the New York State Board of Professional Medical Conduct and on Mount Sinai\u2019s Ethics Committee and Institutional Review Board. He is a past President and Trustee of the New York County Medical Society, and between 2015 and 2017, served as a visiting scholar at the American Enterprise Institute. Dr. Zinberg has written for publications as varied as the Journal of the American Medical Association, the Bulletin of the American College of Surgeons, The Wall Street Journal, City Journal, and law reviews, and authored book chapters on legal and policy issues associated with organ transplantation. Dr. Zinberg earned his B.A. in economics with High Honors, Phi Beta Kappa, from Swarthmore College, his J.D. degree from the Yale Law School, and his M.D. from the Columbia University College of Physicians and Surgeons.","url":"https:\/\/paragoninstitute.org\/author\/joel-zinberg\/"}]}},"_links":{"self":[{"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/posts\/1139"}],"collection":[{"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/comments?post=1139"}],"version-history":[{"count":2,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/posts\/1139\/revisions"}],"predecessor-version":[{"id":3567,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/posts\/1139\/revisions\/3567"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/media\/5159"}],"wp:attachment":[{"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/media?parent=1139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/categories?post=1139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/tags?post=1139"},{"taxonomy":"external-media-outlet","embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/external-media-outlet?post=1139"},{"taxonomy":"featured","embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/featured?post=1139"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/location?post=1139"},{"taxonomy":"publication-type","embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/publication-type?post=1139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}